- Home
- Publications
- Publication Search
- Publication Details
Title
The Potential of CAR T Cell Therapy in Pancreatic Cancer
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 9, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2018-09-25
DOI
10.3389/fimmu.2018.02166
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial
- (2018) Gregory L. Beatty et al. GASTROENTEROLOGY
- Nucleofection with Plasmid DNA for CRISPR/Cas9-Mediated Inactivation of Programmed Cell Death Protein 1 in CD133-Specific CAR T Cells
- (2018) Bian Hu et al. HUMAN GENE THERAPY
- Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors
- (2018) Kristian M. Hargadon et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy
- (2018) Shivani Srivastava et al. JOURNAL OF IMMUNOLOGY
- An “off-the-shelf” fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies
- (2018) Matthew L Cooper et al. LEUKEMIA
- Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
- (2018) Joseph A. Fraietta et al. NATURE MEDICINE
- CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade
- (2018) Theodoros Giavridis et al. NATURE MEDICINE
- Inhibition of Interleukin-10 in the tumor microenvironment can restore mesothelin chimeric antigen receptor T cell activity in pancreatic cancer in vitro
- (2018) Ramesh B. Batchu et al. SURGERY
- Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment
- (2018) Sujita Sukumaran et al. Cancer Discovery
- Emerging strategies for combination checkpoint modulators in cancer immunotherapy
- (2018) Aleksandra Popovic et al. JOURNAL OF CLINICAL INVESTIGATION
- CAR T Cells in Solid Tumors: Blueprints for Building Effective Therapies
- (2018) Hannah M. Knochelmann et al. Frontiers in Immunology
- Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumors
- (2017) Tyrel T. Smith et al. JOURNAL OF CLINICAL INVESTIGATION
- Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels
- (2017) James N. Kochenderfer et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma
- (2017) Frederick L. Locke et al. MOLECULAR THERAPY
- Therapeutic T cell engineering
- (2017) Michel Sadelain et al. NATURE
- A Milestone for CAR T Cells
- (2017) Eric Tran et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
- (2017) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Human CD26high T cells elicit tumor immunity against multiple malignancies via enhanced migration and persistence
- (2017) Stefanie R. Bailey et al. Nature Communications
- FDA Approves Second CAR T-cell Therapy
- (2017) Cancer Discovery
- Genome-Editing Technologies in Adoptive T Cell Immunotherapy for Cancer
- (2017) Nathan Singh et al. Current Hematologic Malignancy Reports
- Efficient growth suppression in pancreatic cancer PDX model by fully human anti-mesothelin CAR-T cells
- (2017) Hua Jiang et al. Protein & Cell
- ZUMA-2: A phase 2 multi-center study evaluating the efficacy of KTE-C19 (Anti-CD19 CAR T cells) in patients with relapsed/refractory Mantle cell lymphoma (R/R MCL)
- (2016) M. Wang et al. ANNALS OF ONCOLOGY
- ZUMA-3: A phase 1/2 multi-center study evaluation the safety and efficacy of KTE-C19 anti-CD19 CAR T cells in adult patients with relapsed/refractory B precursor acute lymphoblastic leukemia (R/R ALL)
- (2016) B. Shah et al. ANNALS OF ONCOLOGY
- Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition
- (2016) Jiangtao Ren et al. CLINICAL CANCER RESEARCH
- Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma
- (2016) Avery D. Posey et al. IMMUNITY
- Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy
- (2016) Mark O'Hara et al. Immunotherapy
- Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition
- (2016) Leonid Cherkassky et al. JOURNAL OF CLINICAL INVESTIGATION
- Translational Implications for Off-the-shelf Immune Cells Expressing Chimeric Antigen Receptors
- (2016) Hiroki Torikai et al. MOLECULAR THERAPY
- Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy
- (2016) Se Jin Im et al. NATURE
- Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors
- (2016) Bing-Lan Zhang et al. Science China-Life Sciences
- Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model
- (2016) Eloah Rabello Suarez et al. Oncotarget
- Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
- (2015) James N. Kochenderfer et al. JOURNAL OF CLINICAL ONCOLOGY
- Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes
- (2015) Ignazio Caruana et al. NATURE MEDICINE
- Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors
- (2015) A. Morello et al. Cancer Discovery
- Identification of Chimeric Antigen Receptors That Mediate Constitutive or Inducible Proliferation of T Cells
- (2015) M. J. Frigault et al. Cancer Immunology Research
- ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells
- (2014) S. Guedan et al. BLOOD
- The Emergence of T-Bodies/CAR T Cells
- (2014) Zelig Eshhar et al. CANCER JOURNAL
- Discovery of Mesothelin and Exploiting It as a Target for Immunotherapy
- (2014) I. Pastan et al. CANCER RESEARCH
- Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
- (2014) L. Rahib et al. CANCER RESEARCH
- Multifactorial T-cell Hypofunction That Is Reversible Can Limit the Efficacy of Chimeric Antigen Receptor-Transduced Human T cells in Solid Tumors
- (2014) E. K. Moon et al. CLINICAL CANCER RESEARCH
- A Novel Chimeric Antigen Receptor Against Prostate Stem Cell Antigen Mediates Tumor Destruction in a Humanized Mouse Model of Pancreatic Cancer
- (2014) Daniel Abate-Daga et al. HUMAN GENE THERAPY
- Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
- (2014) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Expansion of Anti-Mesothelin Specific CD4+ and CD8+ T Cell Responses in Patients with Pancreatic Carcinoma
- (2014) Yuan Chen et al. PLoS One
- Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity
- (2014) P. S. Adusumilli et al. Science Translational Medicine
- Engineered chimeric antigen receptor-expressing T cells for the treatment of pancreatic ductal adenocarcinoma
- (2014) Gregory L Beatty OncoImmunology
- Expression profiling of TCR-engineered T cells demonstrates overexpression of multiple inhibitory receptors in persisting lymphocytes
- (2013) D. Abate-Daga et al. BLOOD
- Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia
- (2013) Eric Tran et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma
- (2013) Chan-Juan Shen et al. Journal of Hematology & Oncology
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies
- (2013) G. L. Beatty et al. Cancer Immunology Research
- Redirecting Gene-Modified T Cells toward Various Cancer Types Using Tagged Antibodies
- (2012) K. Tamada et al. CLINICAL CANCER RESEARCH
- Redirected T Cells That Target Pancreatic Adenocarcinoma Antigens Eliminate Tumors and Metastases in Mice
- (2012) Amit Maliar et al. GASTROENTEROLOGY
- T Cells That Target Carcinoembryonic Antigen Eradicate Orthotopic Pancreatic Carcinomas Without Inducing Autoimmune Colitis in Mice
- (2012) Markus Chmielewski et al. GASTROENTEROLOGY
- B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells
- (2011) J. N. Kochenderfer et al. BLOOD
- Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody Receptor
- (2011) E. K. Moon et al. CLINICAL CANCER RESEARCH
- Redirected Antitumor Activity of Primary Human Lymphocytes Transduced With a Fully Human Anti-mesothelin Chimeric Receptor
- (2011) Evripidis Lanitis et al. MOLECULAR THERAPY
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
- (2011) David L. Porter et al. NEW ENGLAND JOURNAL OF MEDICINE
- Engineered Tcells for pancreatic cancer treatment
- (2011) Usha L. Katari et al. HPB
- Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19
- (2010) J. N. Kochenderfer et al. BLOOD
- Mesothelial proteins are expressed in the human cornea
- (2010) Katerina Jirsova et al. EXPERIMENTAL EYE RESEARCH
- Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
- (2010) Richard A Morgan et al. MOLECULAR THERAPY
- HER2 overexpression correlates with survival after curative resection of pancreatic cancer
- (2009) Masahiro Komoto et al. CANCER SCIENCE
- Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains
- (2009) C. Carpenito et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started